Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ŠPUNAROVÁ Michaela MALČÍKOVÁ Jitka TOM Nikola BORSKÝ Marek BRYCHTOVÁ Yvona DOUBEK Michael PANOVSKÁ Anna SKUHROVÁ FRANCOVÁ Hana ĎURECHOVÁ Kristina BRZOBOHATÁ A. FREIBERGEROVÁ Anna JAROŠOVÁ Marie MRÁZ Marek POSPÍŠILOVÁ Šárka MAYER Jiří TRBUŠEK Martin
Year of publication	2018
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience, Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience.
Related projects:	Predictive stratification of CLL patients for therapy involving monoclonal antibodies targeting CD20 Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V